We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts expect ResMed (RMD - Free Report) to post quarterly earnings of $1.80 per share in its upcoming report, which indicates a year-over-year increase of 8.4%. Revenues are expected to be $1.16 billion, up 12.3% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some ResMed metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Global revenue- Devices' reaching $592.59 million. The estimate points to a change of +9.2% from the year-ago quarter.
The consensus estimate for 'Global revenue- Software as a Service' stands at $146.22 million. The estimate suggests a change of +25.2% year over year.
The combined assessment of analysts suggests that 'Global revenue- Total Sleep and Respiratory Care' will likely reach $1.02 billion. The estimate points to a change of +10.8% from the year-ago quarter.
It is projected by analysts that the 'Global revenue- Masks' will reach $424.11 million. The estimate suggests a change of +13.3% year over year.
The consensus among analysts is that 'U.S., Canada, and Latin America- Devices' will reach $370.33 million. The estimate indicates a year-over-year change of +7.2%.
Analysts predict that the 'U.S., Canada, and Latin America- Masks' will reach $305.12 million. The estimate suggests a change of +13.1% year over year.
Analysts expect 'Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care' to come in at $336.01 million. The estimate suggests a change of +11.4% year over year.
Based on the collective assessment of analysts, 'Combined Europe, Asia, and other markets- Devices' should arrive at $222.27 million. The estimate indicates a change of +12.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Combined Europe, Asia, and other markets- Masks' should come in at $118.99 million. The estimate points to a change of +14% from the year-ago quarter.
ResMed shares have witnessed a change of -1.2% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #2 (Buy), RMD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts expect ResMed (RMD - Free Report) to post quarterly earnings of $1.80 per share in its upcoming report, which indicates a year-over-year increase of 8.4%. Revenues are expected to be $1.16 billion, up 12.3% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some ResMed metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Global revenue- Devices' reaching $592.59 million. The estimate points to a change of +9.2% from the year-ago quarter.
The consensus estimate for 'Global revenue- Software as a Service' stands at $146.22 million. The estimate suggests a change of +25.2% year over year.
The combined assessment of analysts suggests that 'Global revenue- Total Sleep and Respiratory Care' will likely reach $1.02 billion. The estimate points to a change of +10.8% from the year-ago quarter.
It is projected by analysts that the 'Global revenue- Masks' will reach $424.11 million. The estimate suggests a change of +13.3% year over year.
The consensus among analysts is that 'U.S., Canada, and Latin America- Devices' will reach $370.33 million. The estimate indicates a year-over-year change of +7.2%.
Analysts predict that the 'U.S., Canada, and Latin America- Masks' will reach $305.12 million. The estimate suggests a change of +13.1% year over year.
Analysts expect 'Combined Europe, Asia, and other markets- Total Sleep and Respiratory Care' to come in at $336.01 million. The estimate suggests a change of +11.4% year over year.
Based on the collective assessment of analysts, 'Combined Europe, Asia, and other markets- Devices' should arrive at $222.27 million. The estimate indicates a change of +12.7% from the prior-year quarter.
According to the collective judgment of analysts, 'Combined Europe, Asia, and other markets- Masks' should come in at $118.99 million. The estimate points to a change of +14% from the year-ago quarter.
View all Key Company Metrics for ResMed here>>>
ResMed shares have witnessed a change of -1.2% in the past month, in contrast to the Zacks S&P 500 composite's +0.9% move. With a Zacks Rank #2 (Buy), RMD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>